Welcome to our dedicated page for Gelteq news (Ticker: GELS), a resource for investors and traders seeking the latest updates and insights on Gelteq stock.
Gelteq Limited develops gel-based oral delivery systems for prescription drugs, nutraceuticals, pet care, sports, over-the-counter and other product categories. The company focuses on edible gel dosage formats and proprietary formulations designed for oral delivery, including white-label manufacturing and out-licensing of its technology to commercial partners.
GELS news commonly covers preclinical bioavailability and absorption studies, applications for water-soluble, oil-soluble and poorly soluble compounds, and medicinal cannabinoid delivery through the company’s oral gel platform. Updates also include nutraceutical product commercialization, distribution arrangements, sports-performance formulations, manufacturing partnerships and international market expansion.
Gelteq has successfully completed its initial public offering (IPO), raising US$5.2 million through the sale of 1,300,000 ordinary shares at US$4.00 per share. The company's shares began trading on the Nasdaq Global Market under the symbol GELS on October 29, 2024. The Benchmark Company acted as lead managing underwriter, with a 45-day option to purchase up to 195,000 additional shares for over-allotments. Gelteq, a biotechnology company specializing in ingestible gel technology, plans to use the proceeds for manufacturing, marketing, and R&D activities.